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Introduction
Based on data from the United States Renal Data Sys-
tems, there are currently more 400,000 patients with end-
stage renal disease (ESRD) in the United States, and
perhaps more than 1 million patients worldwide. Despite
major improvements in the delivery of state-of-the-art
dialysis treatment, mortality rates among patients with
ESRD remain unacceptably high. Most of the excess
mortality in this population results from cardiovascular
disease. Traditional Framingham risk factors for cardio-
vascular disease, such as diabetes, hypertension, and ab-
normal lipid metabolism, are highly prevalent in patients
with chronic kidney disease. In recent years, there has
been increased recognition of the important role of kid-
ney disease-specific risk factors, which also contribute to
cardiovascular risk. Early stage chronic kidney disease
(CKD) is now recognized as an independent cardiovas-
cular disease risk factor. Within the dialysis population,
postulated risk factors include chronic inflammation with
elevated C-reactive protein, endothelial dysfunction, in-
creased oxidative stress, secondary hyperparathyroidism,
and abnormalities of mineral metabolism. The link be-
tween abnormal mineral metabolism and increased mor-
tality risk in dialysis patients was first reported by Lowrie
and Lew in 1990. Ten years later, Block et al reported the
results of their cross-sectional study, which once again
highlighted an independent association between hyper-
phosphatemia and elevated calcium × phosphorus (Ca ×
P) product and all-cause mortality. Based on these piv-
otal observations, Block and Port were the first to call for
a paradigm shift with recognition of the important con-
tribution of abnormal mineral metabolism to mortality
risk: they recommended more stringent control of serum
phosphorus, Ca × P product, and parathyroid hormone
(PTH) levels in dialysis patients. The recently published
National Kidney Foundation Kidney Disease Outcomes
Initiative (K/DOQI(tm)) Clinical Practice Guidelines for
Bone Metabolism and Disease in Chronic Kidney Dis-
ease has further codified these recommendations, and
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set forth suggested guidelines for treatment of abnormal
mineral metabolism in patients with renal disease.
The topics covered in this supplement to Kidney Inter-
national were presented, in part, in a symposium at the
2004 annual meeting of the Renal Physician’s Associa-
tion. Dr. Eli Friedman’s presentation provides a synopsis
of the clinical manifestations of secondary hyperparathy-
roidism in the setting of chronic kidney disease. Dr.
Darryl Quarles offers a thorough review of pathogenesis
of secondary hyperparathyroidism, including a compre-
hensive outline of the approach to clinical management
of the disorder. Dr. James Bailey’s contribution highlights
the critical role of metabolic acidosis in the pathogenesis
of bone disease and abnormal protein metabolism in the
setting of chronic kidney disease and, thereby, provides a
conceptual framework to support the new K/DOQI rec-
ommendation for aggressive treatment of metabolic aci-
dosis in patients with CKD. Dr. Charles Nolan reviews the
rationale for aggressive treatment of hyperphosphatemia
in dialysis patients, and discusses the clinical implications
of the recently published Calcium Acetate Renagel Eval-
uation (CARE) study.
In summary, it is becoming increasingly apparent that
renal disease is an independent risk factor for cardio-
vascular disease. The pathogenesis of cardiovascular dis-
ease in the setting of CKD is multifactorial, and the
excess cardiovascular mortality among dialysis patients
clearly cannot be explained entirely on the basis of ab-
normal mineral metabolism. Nonetheless, more stringent
control of serum calcium, phosphorus, bicarbonate, and
PTH, as recommended in the K/DOQI guidelines, may
make an important contribution to reducing overall car-
diovascular risk and reducing morbidity due to renal
osteodystrophy.
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